Sector News

Novo Nordisk CEO sees short-term challenges to growth – paper

December 29, 2014
Life sciences
(Reuters) – Novo Nordisk, the world’s biggest insulin maker, is confident about its long-term growth plans but needs to secure approval for its new long-acting insulin Tresiba in the United States, its chief executive said in a newspaper interview on Saturday.
“When we look at the long-term plan … we think that we can demonstrate growth, which is near the ten percent per year,” Chief Executive Lars Rebien Sorensen told Danish daily Berlingske. “But it gets a little challenging in the short term, for it assumes, among other things, that we get Tresiba approved in the U.S.”
Novo Nordisk’s once-daily insulin Tresiba, the company’s big hope for the future, failed to win U.S. approval last year.
“If we gets Tresiba approved in the U.S. I think we will be able to grow on average 10 percent a year over the next five years,” Sorensen said.
The company has delivered annual growth of around 10 percent over the last decade but challenges in the United States have increased, he said.
“The question is how many new generations of insulin … can be developed,” he told the newspaper.
Sorenson pointed to competition in diabetes treatments from rivals such as Sanofi and Eli Lilly. (Reporting by Ole Mikkelsen. Editing by Jane Merriman)

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]